Equity Method and Other Investments - Summary of Financial Information of Reogen (Details) - USD ($) $ in Thousands |
2 Months Ended | 3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|---|
Jun. 30, 2026 |
Jun. 30, 2026 |
Jun. 30, 2025 |
Jun. 30, 2026 |
Jun. 30, 2025 |
|
| Statement of Operations | |||||
| Research and development expense | $ (57,832) | $ (33,495) | $ (89,816) | $ (66,275) | |
| General and administrative expense | $ (12,013) | $ (12,313) | $ (20,941) | $ (21,677) | |
| Reogen | |||||
| Statement of Operations | |||||
| Research and development expense | $ (184,381) | ||||
| General and administrative expense | (20) | ||||
| Other income | 43 | ||||
| Net loss | $ (184,358) | ||||
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of revenue and income classified as other. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Details
|